Concepts (221)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Heterocyclic Compounds, 3-Ring | 7 | 2018 | 275 | 2.97 | Why? |
| HIV Infections | 27 | 2021 | 11620 | 2.68 | Why? |
| Darunavir | 7 | 2021 | 477 | 2.62 | Why? |
| HIV Integrase Inhibitors | 5 | 2019 | 173 | 2.58 | Why? |
| HIV Protease Inhibitors | 7 | 2021 | 434 | 2.52 | Why? |
| Cobicistat | 4 | 2018 | 172 | 2.08 | Why? |
| Drug Interactions | 13 | 2021 | 1653 | 2.06 | Why? |
| Atazanavir Sulfate | 4 | 2018 | 213 | 1.86 | Why? |
| Anti-HIV Agents | 8 | 2019 | 2209 | 1.81 | Why? |
| Ritonavir | 10 | 2021 | 4212 | 1.48 | Why? |
| Anti-Retroviral Agents | 5 | 2019 | 1099 | 1.35 | Why? |
| Pyridones | 7 | 2019 | 738 | 1.18 | Why? |
| Tenofovir | 2 | 2018 | 449 | 1.04 | Why? |
| Polypharmacy | 3 | 2020 | 347 | 0.92 | Why? |
| Polypharmacology | 1 | 2021 | 33 | 0.91 | Why? |
| Anti-Obesity Agents | 2 | 2019 | 52 | 0.90 | Why? |
| Oxazines | 6 | 2018 | 279 | 0.89 | Why? |
| Multiple Chronic Conditions | 1 | 2021 | 115 | 0.84 | Why? |
| Metformin | 2 | 2018 | 640 | 0.83 | Why? |
| Piperazines | 6 | 2018 | 445 | 0.81 | Why? |
| Raltegravir Potassium | 2 | 2018 | 132 | 0.79 | Why? |
| Antiretroviral Therapy, Highly Active | 4 | 2020 | 952 | 0.76 | Why? |
| Calcium Channel Blockers | 3 | 2019 | 367 | 0.75 | Why? |
| Medical History Taking | 1 | 2021 | 350 | 0.74 | Why? |
| Hyperlactatemia | 1 | 2018 | 13 | 0.74 | Why? |
| HIV Seronegativity | 1 | 2018 | 112 | 0.73 | Why? |
| Odontoma | 1 | 2017 | 4 | 0.70 | Why? |
| Therapeutic Equivalency | 1 | 2017 | 64 | 0.70 | Why? |
| Nonprescription Drugs | 1 | 2018 | 78 | 0.69 | Why? |
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2018 | 63 | 0.68 | Why? |
| Dideoxynucleosides | 1 | 2016 | 92 | 0.65 | Why? |
| Rilpivirine | 1 | 2016 | 65 | 0.65 | Why? |
| Risk Adjustment | 1 | 2021 | 730 | 0.64 | Why? |
| Psychotropic Drugs | 2 | 2018 | 396 | 0.63 | Why? |
| Drugs, Generic | 1 | 2017 | 136 | 0.61 | Why? |
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2017 | 256 | 0.59 | Why? |
| Gastrectomy | 1 | 2017 | 225 | 0.59 | Why? |
| Lamivudine | 1 | 2016 | 210 | 0.59 | Why? |
| Drug Prescriptions | 2 | 2021 | 1062 | 0.58 | Why? |
| Fatty Liver | 1 | 2019 | 299 | 0.57 | Why? |
| Adenine | 1 | 2018 | 463 | 0.57 | Why? |
| Drug Monitoring | 3 | 2017 | 1408 | 0.56 | Why? |
| Chemical and Drug Induced Liver Injury | 1 | 2019 | 451 | 0.54 | Why? |
| Viremia | 2 | 2018 | 1020 | 0.53 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 2 | 2021 | 1261 | 0.52 | Why? |
| Drug Substitution | 1 | 2017 | 385 | 0.51 | Why? |
| Biological Availability | 3 | 2019 | 388 | 0.47 | Why? |
| Coinfection | 3 | 2021 | 6820 | 0.43 | Why? |
| Lopinavir | 6 | 2020 | 4308 | 0.39 | Why? |
| Dengue | 1 | 2021 | 1565 | 0.36 | Why? |
| Enterococcus | 1 | 2008 | 73 | 0.35 | Why? |
| Cytochrome P-450 CYP3A | 2 | 2019 | 88 | 0.35 | Why? |
| Hepatitis C, Chronic | 1 | 2017 | 973 | 0.35 | Why? |
| HIV | 3 | 2020 | 1116 | 0.34 | Why? |
| Ambulatory Care Facilities | 1 | 2019 | 2063 | 0.33 | Why? |
| Drug Administration Schedule | 4 | 2019 | 2324 | 0.32 | Why? |
| Pharmaceutical Preparations | 1 | 2021 | 1897 | 0.32 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2020 | 4545 | 0.30 | Why? |
| Drug Combinations | 4 | 2020 | 3852 | 0.29 | Why? |
| Streptococcal Infections | 1 | 2008 | 255 | 0.28 | Why? |
| Referral and Consultation | 1 | 2020 | 4816 | 0.27 | Why? |
| Hypoglycemic Agents | 1 | 2017 | 2165 | 0.27 | Why? |
| Adrenal Cortex Hormones | 1 | 2021 | 6537 | 0.26 | Why? |
| CD4 Lymphocyte Count | 3 | 2018 | 1517 | 0.26 | Why? |
| Endocarditis, Bacterial | 1 | 2008 | 344 | 0.25 | Why? |
| HIV-1 | 5 | 2019 | 3365 | 0.25 | Why? |
| Drug Therapy, Combination | 5 | 2019 | 7268 | 0.25 | Why? |
| Glucocorticoids | 1 | 2019 | 4431 | 0.25 | Why? |
| Antidepressive Agents | 2 | 2018 | 509 | 0.24 | Why? |
| Renal Insufficiency, Chronic | 1 | 2017 | 2654 | 0.24 | Why? |
| Italy | 11 | 2021 | 38444 | 0.23 | Why? |
| Pharmacokinetics | 1 | 2021 | 41 | 0.23 | Why? |
| Humans | 47 | 2021 | 930598 | 0.23 | Why? |
| Potentially Inappropriate Medication List | 1 | 2021 | 55 | 0.22 | Why? |
| Hospitals | 1 | 2020 | 11793 | 0.21 | Why? |
| Xenobiotics | 1 | 2019 | 37 | 0.20 | Why? |
| Drug Antagonism | 1 | 2018 | 24 | 0.19 | Why? |
| Intervertebral Disc Displacement | 1 | 2019 | 25 | 0.19 | Why? |
| Trigeminal Neuralgia | 1 | 2019 | 19 | 0.19 | Why? |
| Male | 25 | 2021 | 367725 | 0.18 | Why? |
| Glucuronosyltransferase | 1 | 2017 | 24 | 0.17 | Why? |
| Therapies, Investigational | 1 | 2020 | 235 | 0.17 | Why? |
| Middle Aged | 18 | 2020 | 270681 | 0.17 | Why? |
| Clinical Trials as Topic | 4 | 2020 | 7330 | 0.17 | Why? |
| PPAR alpha | 1 | 2017 | 36 | 0.17 | Why? |
| Viral Load | 4 | 2020 | 15850 | 0.17 | Why? |
| Injections, Subcutaneous | 1 | 2019 | 647 | 0.16 | Why? |
| Hypertension | 1 | 2018 | 8895 | 0.16 | Why? |
| Preliminary Data | 1 | 2018 | 457 | 0.16 | Why? |
| Injections, Intramuscular | 1 | 2019 | 800 | 0.16 | Why? |
| Retrospective Studies | 10 | 2021 | 105322 | 0.16 | Why? |
| Linezolid | 1 | 2017 | 160 | 0.16 | Why? |
| Quinolones | 1 | 2018 | 167 | 0.16 | Why? |
| HIV Seropositivity | 1 | 2018 | 320 | 0.15 | Why? |
| Diabetes Mellitus, Type 2 | 1 | 2017 | 6166 | 0.15 | Why? |
| Female | 21 | 2021 | 380317 | 0.15 | Why? |
| Antiviral Agents | 5 | 2020 | 41703 | 0.15 | Why? |
| Genome, Bacterial | 1 | 2019 | 446 | 0.15 | Why? |
| Drug Dosage Calculations | 1 | 2016 | 243 | 0.15 | Why? |
| Kidney Function Tests | 1 | 2017 | 520 | 0.14 | Why? |
| Prednisone | 1 | 2019 | 652 | 0.14 | Why? |
| Diabetes Mellitus, Type 1 | 1 | 2008 | 1969 | 0.13 | Why? |
| Dengue Virus | 1 | 2021 | 910 | 0.13 | Why? |
| Dose-Response Relationship, Drug | 3 | 2019 | 3776 | 0.13 | Why? |
| Aged | 12 | 2021 | 215776 | 0.13 | Why? |
| Adult | 14 | 2021 | 244371 | 0.13 | Why? |
| Depression | 1 | 2018 | 14116 | 0.13 | Why? |
| Communicable Diseases, Imported | 1 | 2021 | 843 | 0.12 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 711 | 0.12 | Why? |
| Treatment Failure | 1 | 2018 | 2106 | 0.12 | Why? |
| Anti-Bacterial Agents | 2 | 2017 | 10083 | 0.11 | Why? |
| Staphylococcal Infections | 2 | 2019 | 1099 | 0.11 | Why? |
| Kaplan-Meier Estimate | 2 | 2018 | 4260 | 0.11 | Why? |
| Staphylococcus aureus | 1 | 2017 | 844 | 0.11 | Why? |
| Drug Resistance, Viral | 1 | 2017 | 1083 | 0.10 | Why? |
| Research Design | 3 | 2020 | 5830 | 0.10 | Why? |
| Area Under Curve | 1 | 2017 | 2564 | 0.10 | Why? |
| Antipsychotic Agents | 1 | 2018 | 887 | 0.10 | Why? |
| Proportional Hazards Models | 3 | 2018 | 6543 | 0.10 | Why? |
| Glycated Hemoglobin A | 1 | 2017 | 1316 | 0.09 | Why? |
| Diagnostic Tests, Routine | 1 | 2020 | 2643 | 0.09 | Why? |
| Treatment Outcome | 4 | 2021 | 51732 | 0.09 | Why? |
| Leukocidins | 2 | 2019 | 47 | 0.09 | Why? |
| Community-Acquired Infections | 2 | 2019 | 2328 | 0.09 | Why? |
| Diabetic Neuropathies | 1 | 2008 | 64 | 0.09 | Why? |
| Methylprednisolone | 1 | 2019 | 2107 | 0.09 | Why? |
| Drug Evaluation, Preclinical | 1 | 2019 | 3347 | 0.08 | Why? |
| Risk Assessment | 3 | 2021 | 25439 | 0.08 | Why? |
| Republic of Korea | 1 | 2020 | 5858 | 0.08 | Why? |
| Hydroxychloroquine | 2 | 2020 | 12447 | 0.08 | Why? |
| Diabetic Angiopathies | 1 | 2008 | 146 | 0.08 | Why? |
| Cesarean Section | 1 | 2017 | 2089 | 0.08 | Why? |
| Cohort Studies | 3 | 2020 | 36005 | 0.08 | Why? |
| Diagnosis, Differential | 1 | 2021 | 7220 | 0.08 | Why? |
| Pandemics | 7 | 2020 | 389249 | 0.07 | Why? |
| Patient Safety | 1 | 2020 | 4885 | 0.07 | Why? |
| Germany | 1 | 2020 | 9196 | 0.07 | Why? |
| Patient Discharge | 1 | 2021 | 5696 | 0.07 | Why? |
| Alanine | 2 | 2020 | 5687 | 0.07 | Why? |
| Comorbidity | 2 | 2018 | 34796 | 0.06 | Why? |
| Lipodystrophy | 1 | 2002 | 18 | 0.06 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.06 | Why? |
| Biomedical Research | 2 | 2020 | 5270 | 0.06 | Why? |
| Coronavirus Infections | 6 | 2020 | 253789 | 0.06 | Why? |
| Risk Factors | 4 | 2020 | 71621 | 0.06 | Why? |
| Aged, 80 and over | 4 | 2021 | 88759 | 0.06 | Why? |
| Interleukin-6 | 1 | 2021 | 7522 | 0.06 | Why? |
| Age Factors | 2 | 2020 | 21039 | 0.06 | Why? |
| Spain | 1 | 2020 | 15545 | 0.06 | Why? |
| Travel | 1 | 2021 | 7220 | 0.06 | Why? |
| Drug Repositioning | 1 | 2020 | 5683 | 0.06 | Why? |
| Young Adult | 3 | 2020 | 93724 | 0.05 | Why? |
| Spinal Puncture | 1 | 2000 | 95 | 0.05 | Why? |
| Emetine | 1 | 2020 | 70 | 0.05 | Why? |
| Meningitis, Cryptococcal | 1 | 2000 | 79 | 0.05 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 13720 | 0.05 | Why? |
| Hospitalization | 2 | 2021 | 54280 | 0.05 | Why? |
| Animals | 3 | 2019 | 78931 | 0.05 | Why? |
| Intracranial Hypertension | 1 | 2000 | 111 | 0.05 | Why? |
| Disease Progression | 1 | 2018 | 13580 | 0.05 | Why? |
| AIDS-Related Opportunistic Infections | 1 | 2000 | 260 | 0.04 | Why? |
| Antipyretics | 1 | 2018 | 107 | 0.04 | Why? |
| Drugs, Investigational | 1 | 2020 | 198 | 0.04 | Why? |
| Exotoxins | 1 | 2017 | 54 | 0.04 | Why? |
| Adipose Tissue | 1 | 2002 | 612 | 0.04 | Why? |
| Pharmacogenomic Variants | 1 | 2017 | 112 | 0.04 | Why? |
| Prognosis | 1 | 2020 | 32490 | 0.04 | Why? |
| Multilocus Sequence Typing | 1 | 2017 | 264 | 0.04 | Why? |
| Reverse Transcriptase Inhibitors | 1 | 2018 | 309 | 0.04 | Why? |
| SARS Virus | 1 | 2020 | 13021 | 0.04 | Why? |
| Mutation | 1 | 2017 | 12376 | 0.04 | Why? |
| Bacterial Toxins | 1 | 2017 | 185 | 0.04 | Why? |
| Time Factors | 1 | 2019 | 31397 | 0.04 | Why? |
| Mental Disorders | 1 | 2018 | 6742 | 0.04 | Why? |
| Cardiovascular Diseases | 1 | 2020 | 11497 | 0.04 | Why? |
| Abscess | 1 | 2017 | 234 | 0.04 | Why? |
| Virulence Factors | 1 | 2017 | 338 | 0.03 | Why? |
| Pregnancy | 1 | 2017 | 23879 | 0.03 | Why? |
| Severity of Illness Index | 2 | 2020 | 48226 | 0.03 | Why? |
| RNA, Viral | 1 | 2020 | 32276 | 0.03 | Why? |
| Observational Studies as Topic | 1 | 2020 | 1887 | 0.03 | Why? |
| Myocardial Infarction | 1 | 2008 | 3361 | 0.03 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.03 | Why? |
| Fever | 1 | 2008 | 7795 | 0.03 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.03 | Why? |
| Publishing | 1 | 2020 | 990 | 0.03 | Why? |
| Adolescent | 1 | 2020 | 86841 | 0.03 | Why? |
| Netherlands | 1 | 2019 | 3533 | 0.02 | Why? |
| Bayes Theorem | 1 | 2019 | 3237 | 0.02 | Why? |
| Taste Disorders | 1 | 2020 | 1720 | 0.02 | Why? |
| Microbial Sensitivity Tests | 1 | 2017 | 2886 | 0.02 | Why? |
| Self Report | 1 | 2020 | 3802 | 0.02 | Why? |
| Periodicals as Topic | 1 | 2020 | 1492 | 0.02 | Why? |
| Research | 1 | 2020 | 2115 | 0.02 | Why? |
| Genomics | 1 | 2019 | 3118 | 0.02 | Why? |
| Outpatients | 1 | 2019 | 3417 | 0.02 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2017 | 3607 | 0.02 | Why? |
| Logistic Models | 1 | 2018 | 9089 | 0.02 | Why? |
| Adenosine Monophosphate | 1 | 2020 | 5652 | 0.01 | Why? |
| Cross-Sectional Studies | 2 | 2020 | 53120 | 0.01 | Why? |
| Sex Factors | 1 | 2018 | 11014 | 0.01 | Why? |
| Probability | 1 | 2002 | 923 | 0.01 | Why? |
| Sex Distribution | 1 | 2002 | 2083 | 0.01 | Why? |
| Infant | 1 | 2017 | 30274 | 0.01 | Why? |
| China | 1 | 2020 | 50654 | 0.01 | Why? |
| Age Distribution | 1 | 2002 | 3567 | 0.01 | Why? |
| Histamine | 1 | 1972 | 61 | 0.01 | Why? |
| Multivariate Analysis | 1 | 2002 | 5440 | 0.01 | Why? |
| Serotonin | 1 | 1972 | 137 | 0.01 | Why? |
| Phagocytosis | 1 | 1972 | 409 | 0.01 | Why? |
| Carbon | 1 | 1972 | 269 | 0.01 | Why? |
| Pulmonary Circulation | 1 | 1972 | 207 | 0.01 | Why? |
| Bradykinin | 1 | 1972 | 203 | 0.01 | Why? |
| Epinephrine | 1 | 1972 | 323 | 0.01 | Why? |
| Child | 1 | 2017 | 70012 | 0.01 | Why? |
| Incidence | 1 | 2002 | 25622 | 0.00 | Why? |
| Microscopy, Electron | 1 | 1972 | 830 | 0.00 | Why? |
| Pulmonary Edema | 1 | 1972 | 430 | 0.00 | Why? |
| Bronchi | 1 | 1972 | 1048 | 0.00 | Why? |
| Rats | 1 | 1972 | 2764 | 0.00 | Why? |
| Epithelial Cells | 1 | 1972 | 3508 | 0.00 | Why? |